# Sleep & Recovery Peptide FAQ — DSIP and Selank — Peptide Ways

> Frequently asked questions about DSIP (Delta Sleep-Inducing Peptide) and Selank — two nootropic research peptides — answered from the peer-reviewed literature, with citations and frank disclosure of what remains unknown.

Direct, citation-anchored answers to what readers most often want to know about DSIP and Selank — including the questions the literature answers with "we still don't know."

## What is DSIP peptide?

DSIP stands for Delta Sleep-Inducing Peptide. It is a naturally occurring chain of nine amino acids (sequence: Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 from the cerebral venous blood of sleeping rabbits. When infused directly into rabbit brains, it produced specific enhancement of the slow delta and spindle brain waves associated with deep, restorative sleep [6]. Its INN (international non-proprietary name) is Emideltide, though no Emideltide drug product has ever been approved or marketed by any regulator. It has been studied for forty-plus years and still has no identified receptor, gene, or precursor protein [2].

## What is DSIP used for in research?

In published research, DSIP has been studied across several contexts: sleep physiology (enhancing slow-wave EEG activity in animals [6] and a small human insomnia pilot [5]), HPA-axis modulation (reducing ACTH immunoreactivity in men [4]), potential longevity effects in a mouse model (the Deltaran preparation extended lifespan and reduced tumor incidence [3]), and neuroprotection after focal stroke in rats [7]. More recently, a BBB-crossing fusion analog was tested in an insomnia mouse model [1]. The thread running through the research is an organism-wide stress-modulation and recovery signal — but no modern controlled human trial has confirmed any of these effects in people.

## What are the reported benefits of DSIP?

In the one small human insomnia study (six middle-aged chronic insomniacs, 1981), intravenous DSIP produced longer sleep duration, fewer nighttime interruptions, slightly more REM, and no daytime sedation [5]. In community self-experimentation accounts — **anecdotal, not clinical evidence** — responders describe an easier transition into sleep, more restorative-feeling deep sleep, waking clear-headed rather than groggy, and vivid dream recall. Some also describe a calmer, lower-stress feeling extending into the day. These reports are inconsistent: a large share of people report no benefit at all, and community estimates suggest only roughly half of people who try it notice a meaningful effect.

## Does DSIP really work?

That depends on what "work" means, and the honest answer is: inconsistently, and for uncertain reasons. The founding EEG work in rabbits was real and reproducible [6]. The 1981 human insomnia data were encouraging but came from six people and were never followed up with larger trials [5]. The 2006 Journal of Neurochemistry review — the field's own assessment — called the sleep evidence "extremely poorly documented and still weak" and noted that no DSIP receptor, gene, or precursor has ever been found [2]. In community experience, a substantial minority report clear benefit; a substantial minority report nothing. This is not a compound with a clean, consistent record of doing its named job in people.

## What is Selank?

Selank is a synthetic heptapeptide (seven amino acids: Thr-Lys-Pro-Arg-Pro-Gly-Pro) designed by extending the endogenous immune peptide tuftsin with a stabilizing tail. It was developed in Russia and is registered there as a prescription anxiolytic. Outside Russia it has no regulatory approval and is sold as a research chemical. Its pharmacological profile includes positive allosteric modulation of GABA receptors, inhibition of enkephalin-degrading enzymes, upregulation of BDNF in the hippocampus, and modulation of cytokine balance — a combination that sets it apart from classical benzodiazepine anxiolytics [8][11][12].

## What does Selank do?

In animal models and limited human clinical research, Selank reduces anxiety without causing sedation, muscle relaxation, or the dependence risk associated with benzodiazepines [8]. In a chronic rat stress model, it enhanced the anxiety-reducing effect of diazepam when the two were combined [9]. At the gene level it shifted expression of GABA-pathway genes in rat frontal cortex in a direction consistent with increased GABAergic tone [10]. In a human study, it modulated cytokine balance in patients with anxiety-asthenic disorders, confirming an immunomodulatory action on top of the neurological one [12]. In community accounts (**anecdotal, not clinical evidence**), it is most often described as "the edge taken off" without heaviness or fog.

## What is Selank peptide used for?

In Russia, Selank is registered for anxiety and anxiety-asthenic disorders, used under medical supervision. In the international research and nootropic communities it is used situationally for performance anxiety (presentations, exams, high-stakes conversations) and as a daily anti-anxiety tool that people hope to use without dependence risk. Some use it to improve sleep on anxious nights, reasoning that quieting racing thoughts allows sleep to come naturally [8]. None of these represent FDA-approved or clinically validated use; this site does not endorse or recommend any of them.

## How does Selank work?

Two main mechanisms are described in the research. First, Selank acts as a positive allosteric modulator of GABA receptor binding — it enhances the receptor's responsiveness to the brain's own calming neurotransmitter GABA, in a subtype-selective and concentration-dependent way that differs from the benzodiazepine binding site [8]. Second, it inhibits the enzymes (enkephalinases) that break down endogenous enkephalins, stabilizing these natural opioid-like peptides and engaging the opioid-anxiety system [8]. Additionally, it upregulates BDNF in the hippocampus [11] and shifts immune cytokine balance [12]. Whether these mechanisms work in the same way in unsupervised human use at research-chemical doses is not established.

## How are DSIP and Selank different?

The most fundamental difference is mechanistic clarity. DSIP, despite being naturally occurring and named for sleep induction, has no identified receptor or confirmed mechanism after more than forty years of research [2]. Selank is synthetic and has two characterized pathways: GABAergic allosteric modulation and enkephalinase inhibition [8]. In terms of evidence, DSIP's best human data are a 1981 six-person insomnia trial; Selank's are a supervised clinical study in anxious patients [5][12]. Selank is registered as a prescription drug in Russia; DSIP has no regulatory registration anywhere. In the community, Selank produces more consistent anecdotal reports than DSIP, for which a large share of users report nothing at all.

## Are DSIP or Selank approved medicines?

DSIP is not approved as a medicine by the FDA, EMA, or any other major regulator. Selank is registered as a prescription anxiolytic in Russia but is not approved by the FDA or EMA. Outside Russia, both are sold for laboratory research only and are not intended for human consumption [2][8]. Both are unapproved pharmacological agents, and WADA's S0 catch-all category for non-approved substances may apply to either in sport contexts.

## Is it safe to use DSIP and Selank together?

There are no published human studies, and no animal studies we are aware of, examining DSIP and Selank in combination. DSIP has proposed opioid-system interactions in its literature [2] and plausible HPA-axis effects [4]; Selank touches GABAergic, opioid, monoaminergic, and immune pathways [8]. Stacking two agents with unknown or multi-system pharmacology, in the absence of combination safety data, is a research-design question, not a clinical recommendation this desk can speak to. Nothing in this site constitutes medical advice.

## What should I know before reading DSIP or Selank research?

Three things: First, both are research chemicals — unregulated, with no pharmaceutical-grade quality guarantee in online supply. Second, the human evidence for DSIP is extremely thin and inconsistent [2], and the human evidence for Selank is limited to small studies from a single research region [8]. Third, for sleep trouble or anxiety that is persistent or impairing, these are not established substitutes for evaluation by a qualified clinician. This site is a literature digest; it summarizes what was studied, names what is unknown, and never recommends a human dose or use.

---

A literature digest tracking the published evidence on sleep and recovery peptides — citations in, no prescriptions out.